Published in Pharmacoeconomics on February 01, 2011
Long-term effectiveness of ranibizumab for age-related macular degeneration and diabetic macular edema. Clin Interv Aging (2013) 0.99
Cost-effectiveness of bevacizumab and ranibizumab for newly diagnosed neovascular macular degeneration. Ophthalmology (2014) 0.99
Natural product inhibitors of ocular angiogenesis. Exp Eye Res (2014) 0.97
Synthesis and mechanistic studies of a novel homoisoflavanone inhibitor of endothelial cell growth. PLoS One (2014) 0.94
Cost-effectiveness of ranibizumab and bevacizumab for age-related macular degeneration: 2-year findings from the IVAN randomised trial. BMJ Open (2014) 0.94
The first synthesis of the antiangiogenic homoisoflavanone, cremastranone. Org Biomol Chem (2014) 0.88
Visual impairment as a function of visual acuity in both eyes and its impact on patient reported preferences. PLoS One (2013) 0.87
Combination of ranibizumab with photodynamic therapy vs ranibizumab monotherapy in the treatment of age-related macular degeneration: a systematic review and meta-analysis of randomized controlled trials. Int J Ophthalmol (2014) 0.82
Toxicity of endogenous peroxynitrite and effects of puerarin on transplanted retinal pigment epithelial sheets in the subretinal space in mice. Int J Ophthalmol (2011) 0.79
Different Strategies for the Treatment of Age-Related Macular Degeneration in China: An Economic Evaluation. J Ophthalmol (2016) 0.78
Cost-effectiveness of bevacizumab and ranibizumab for newly diagnosed neovascular macular degeneration (an American Ophthalmological Society thesis). Trans Am Ophthalmol Soc (2013) 0.78
What the comprehensive economics of blindness and visual impairment can help us understand. Indian J Ophthalmol (2012) 0.77
The Clinical Effectiveness and Cost-Effectiveness of Screening for Age-Related Macular Degeneration in Japan: A Markov Modeling Study. PLoS One (2015) 0.75
DNA Aptamer Based Nanodrugs: Molecular Engineering for Efficiency. Chem Asian J (2015) 0.75
Cooperation of German ophthalmologists in routine care of patients with neovascular age-related macular degeneration: results of the non-interventional BRIDGE study. Graefes Arch Clin Exp Ophthalmol (2015) 0.75
Principles of good practice for budget impact analysis: report of the ISPOR Task Force on good research practices--budget impact analysis. Value Health (2007) 3.93
Interpreting indirect treatment comparisons and network meta-analysis for health-care decision making: report of the ISPOR Task Force on Indirect Treatment Comparisons Good Research Practices: part 1. Value Health (2011) 3.88
Systematic review: Effects, design choices, and context of pay-for-performance in health care. BMC Health Serv Res (2010) 2.70
Patient management after noninvasive cardiac imaging results from SPARC (Study of myocardial perfusion and coronary anatomy imaging roles in coronary artery disease). J Am Coll Cardiol (2012) 2.60
Clinical and economic outcomes in critically ill patients with nosocomial catheter-related bloodstream infections. Clin Infect Dis (2005) 2.26
Education in pharmacoeconomics: an international multidisciplinary view. Pharmacoeconomics (2004) 2.25
A health economic evaluation of aspirin in the primary prevention of cardiovascular disease in Japan. Intern Med (2007) 2.17
A decadal view of biodiversity informatics: challenges and priorities. BMC Ecol (2013) 2.01
Quality of life after intensive care: a systematic review of the literature. Crit Care Med (2010) 1.96
The family impact and costs of migraine. Am J Manag Care (2004) 1.72
Discounting health effects in pharmacoeconomic evaluations: current controversies. Pharmacoeconomics (2005) 1.71
Identifying unprovoked thromboembolism patients at low risk for recurrence who can discontinue anticoagulant therapy. CMAJ (2008) 1.71
Life events as predictors of mania and depression in bipolar I disorder. J Abnorm Psychol (2008) 1.60
Ultrafast graphene oxide humidity sensors. ACS Nano (2013) 1.59
A novel tumor necrosis factor-mediated mechanism of direct epithelial sodium channel activation. Am J Respir Crit Care Med (2014) 1.55
A health economic model to assess the long-term effects and cost-effectiveness of orlistat in obese type 2 diabetic patients. Diabetes Care (2002) 1.50
Adjuvant high-dose bolus interleukin-2 for patients with high-risk renal cell carcinoma: a cytokine working group randomized trial. J Clin Oncol (2003) 1.49
The safety and efficacy of dressings with silver - addressing clinical concerns. Int Wound J (2007) 1.48
The Society for Immunotherapy of Cancer consensus statement on tumour immunotherapy for the treatment of cutaneous melanoma. Nat Rev Clin Oncol (2013) 1.46
Health promotion in individuals with mental disorders: a cluster preference randomized controlled trial. BMC Public Health (2013) 1.44
Preoperative chemosensitivity testing as Predictor of Treatment benefit in Adjuvant stage III colon cancer (PePiTA): protocol of a prospective BGDO (Belgian Group for Digestive Oncology) multicentric study. BMC Cancer (2013) 1.43
Evidence of a novel site mediating anandamide-induced negative inotropic and coronary vasodilatator responses in rat isolated hearts. Br J Pharmacol (2002) 1.41
Thinking ahead--the rising tide of AIDS orphans. S Afr Med J (2005) 1.41
Economic evaluations in healthcare: comments on a recent article. Reprod Biomed Online (2005) 1.40
Air pollution and daily mortality in a city with low levels of pollution. Environ Health Perspect (2003) 1.39
Burden of illness of diabetic macular edema: literature review. Curr Med Res Opin (2010) 1.39
Silver-containing dressings: availability concerns. Ostomy Wound Manage (2010) 1.38
Forecasting the cytokine storm following systemic interleukin (IL)-2 administration. J Transl Med (2004) 1.27
Retro-orbital injection in adult zebrafish. J Vis Exp (2009) 1.26
Healthcare costs of acute and chronic pain associated with a diagnosis of herpes zoster. J Am Geriatr Soc (2007) 1.25
Global monitoring of autumn gene expression within and among phenotypically divergent populations of Sitka spruce (Picea sitchensis). New Phytol (2008) 1.21
Identification of the zebrafish maternal and paternal transcriptomes. Development (2013) 1.14
Agonist of growth hormone-releasing hormone reduces pneumolysin-induced pulmonary permeability edema. Proc Natl Acad Sci U S A (2012) 1.14
Activated partial thromboplastin time and risk of future venous thromboembolism. Am J Med (2008) 1.12
Daily cost of antimicrobial therapy in patients with Intensive Care Unit-acquired, laboratory-confirmed bloodstream infection. Int J Antimicrob Agents (2008) 1.11
A multiinstitutional, multidisciplinary model for developing and teaching translational research in health disparities. Clin Transl Sci (2011) 1.09
Impact of guidance from a computer-aided multispectral digital skin lesion analysis device on decision to biopsy lesions clinically suggestive of melanoma. Arch Dermatol (2012) 1.09
What reimbursement for coronary revascularization with drug-eluting stents? Eur J Health Econ (2004) 1.09
The ties that bind: an integrative framework of physician-hospital alignment. BMC Health Serv Res (2011) 1.08
Effectiveness and cost-effectiveness of lifestyle interventions on physical activity and eating habits in persons with severe mental disorders: a systematic review. Int J Behav Nutr Phys Act (2011) 1.08
Clinical relapses of multiple sclerosis are associated with 'novel' valleys in natural killer cell functional activity. J Neuroimmunol (2003) 1.07
Antiretroviral therapy and sexual behavior in Uganda: a cohort study. AIDS (2011) 1.06
Thought and Language Index: an instrument for assessing thought and language in schizophrenia. Br J Psychiatry (2002) 1.05
GPR87 is an overexpressed G-protein coupled receptor in squamous cell carcinoma of the lung. Dis Markers (2008) 1.04
Cost-effectiveness of 123I-FP-CIT SPECT in the differential diagnosis of essential tremor and Parkinson's disease in Italy. Mov Disord (2008) 1.03
The impact of disease stage on direct medical costs of HIV management: a review of the international literature. Pharmacoeconomics (2010) 1.02
Health related quality of life in coronary patients and its association with their cardiovascular risk profile: results from the EUROASPIRE III survey. Int J Cardiol (2012) 1.02
Cost-effectiveness of ranibizumab in treatment of diabetic macular oedema (DME) causing visual impairment: evidence from the RESTORE trial. Br J Ophthalmol (2012) 1.01
Monoterpene-induced molecular responses in Arabidopsis thaliana. Phytochemistry (2008) 1.01
The Dual Role of TNF in Pulmonary Edema. J Cardiovasc Dis Res (2010) 0.99
Structural brain abnormalities and suicidal behavior in borderline personality disorder. J Psychiatr Res (2012) 0.99
Comparison of detailed and succinct cohort modelling approaches in a multi-regional evaluation of cervical cancer vaccination. Vaccine (2008) 0.98
Using the TIME model in Spectrum to estimate tuberculosis-HIV incidence and mortality. AIDS (2014) 0.97
Psychological well-being and socio-economic hardship among AIDS orphans and other vulnerable children in Guinea. AIDS Care (2009) 0.97
Defined and refined: criteria for identifying wound infection revisited. Br J Community Nurs (2004) 0.96
Differential pricing of new pharmaceuticals in lower income European countries. Expert Rev Pharmacoecon Outcomes Res (2013) 0.96
Will GnRH antagonists improve prostate cancer treatment? Trends Endocrinol Metab (2008) 0.94
Vaccination against herpes zoster and postherpetic neuralgia in France: a cost-effectiveness analysis. Expert Rev Pharmacoecon Outcomes Res (2013) 0.94
Conformationally restricted analogs of deoxynegamycin. Bioorg Med Chem Lett (2004) 0.93
Antipsychotic-induced type 2 diabetes: evidence from a large health plan database. J Clin Psychopharmacol (2003) 0.93
Patient-reported visual function outcomes improve after ranibizumab treatment in patients with vision impairment due to diabetic macular edema: randomized clinical trial. JAMA Ophthalmol (2013) 0.93
Reflections on market access for personalized medicine: recommendations for Europe. Value Health (2013) 0.93
Health technology assessments in personalized medicine: illustrations for cost-effectiveness analysis. Expert Rev Pharmacoecon Outcomes Res (2011) 0.92
Randomized study of the effect of local anesthetic volume and concentration on the duration of peripheral nerve blockade. Reg Anesth Pain Med (2012) 0.91
Pay-for-performance step-by-step: introduction to the MIMIQ model. Health Policy (2010) 0.91
A multi-country economic evaluation of low-dose aspirin in the primary prevention of cardiovascular disease. Pharmacoeconomics (2006) 0.90
Methods for claims-based pharmacoeconomic studies in psychosis. Pharmacoeconomics (2002) 0.89
Thoracoabdominal esophageal duplication cyst. J Am Coll Surg (2002) 0.89
EPICOR (long-tErm follow-up of antithrombotic management Patterns In acute CORonary syndrome patients) study: rationale, design, and baseline characteristics. Am Heart J (2012) 0.89
Fronto-limbic function in unaffected offspring at familial risk for bipolar disorder during an emotional working memory paradigm. Dev Cogn Neurosci (2013) 0.88
Rapid suppression of plasma testosterone levels and tumor growth in the dunning rat model treated with degarelix, a new gonadotropin-releasing hormone antagonist. J Pharmacol Exp Ther (2006) 0.88
The equity dimension in evaluations of the quality and outcomes framework: a systematic review. BMC Health Serv Res (2011) 0.88
The effect of a depth gradient on the mating behavior, oviposition site preference, and embryo production in the zebrafish, Danio rerio. Zebrafish (2008) 0.88
Relation of elevated plasma renin activity at baseline to cardiac events in patients with angiographically proven coronary artery disease. Am J Cardiol (2010) 0.88
Cost-effectiveness analysis of bicalutamide (Casodex) for adjuvant treatment of early prostate cancer. Value Health (2004) 0.87
Antibiotics GE23077, novel inhibitors of bacterial RNA polymerase. Part 3: Chemical derivatization. Bioorg Med Chem Lett (2005) 0.87
Giant Virchow-Robin spaces: functional magnetic resonance imaging and tractography. Arch Neurol (2010) 0.87
Prolonged enoxaparin therapy to prevent venous thromboembolism after primary hip or knee replacement. A cost-utility analysis. Arch Orthop Trauma Surg (2004) 0.87
The cost effectiveness of 123I-FP-CIT SPECT imaging in patients with an uncertain clinical diagnosis of parkinsonism. Eur J Nucl Med Mol Imaging (2008) 0.87
Alzheimer's disease treatment: assessing caregiver preferences for mode of treatment delivery. Adv Ther (2009) 0.86
A multi-country health economic evaluation of highly concentrated N-3 polyunsaturated fatty acids in secondary prevention after myocardial infarction. Pharmacoeconomics (2006) 0.86
Control of sexually transmitted infections for HIV prevention. Lancet (2008) 0.86
Economic impact of enoxaparin after acute ischemic stroke based on PREVAIL. Clin Appl Thromb Hemost (2010) 0.86
Valuing prevention through economic evaluation: some considerations regarding the choice of discount model for health effects with focus on infectious diseases. Pharmacoeconomics (2004) 0.85
Topical silver-impregnated dressings and the importance of the dressing technology. Int Wound J (2009) 0.85
A health economic model to assess the cost-effectiveness of pegylated interferon alpha-2a and ribavirin in patients with moderate chronic hepatitis C and persistently normal alanine aminotransferase levels. Acta Gastroenterol Belg (2007) 0.85
Voriconazole treatment of invasive aspergillosis: real-world versus health-economic model results. Clin Drug Investig (2008) 0.85
A cost-effectiveness model of escitalopram, citalopram,and venlafaxine as first-line treatment for major depressive disorder in Belgium. Clin Ther (2005) 0.85
Potential roles of adenosine deaminase-2 in diabetic retinopathy. Biochem Biophys Res Commun (2013) 0.84
Cost effectiveness of darunavir/ritonavir 600/100 mg bid in protease inhibitor-experienced, HIV-1-infected adults in Belgium, Italy, Sweden and the UK. Pharmacoeconomics (2010) 0.84
Defense mechanisms against herbivory in Picea: sequence evolution and expression regulation of gene family members in the phenylpropanoid pathway. BMC Genomics (2011) 0.84
Economic burden of pertussis and the impact of immunization. Pediatr Infect Dis J (2005) 0.84
Determinants of coital frequency among married women in Central African Republic: the role of female genital cutting. J Biosoc Sci (2002) 0.84
N- and C-terminal modifications of negamycin. Bioorg Med Chem Lett (2003) 0.83
Adjuvant dexamethasone for bupivacaine sciatic and ankle blocks: results from 2 randomized placebo-controlled trials. Reg Anesth Pain Med (2013) 0.83